Dr Yvette Drew
| Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10 | 2023 |
|
Hannah Smith Dr Elaine Willmore Dr Asima Mukhopadhyay Dr Yvette Drew Professor Nicola Curtin et al. | Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling | 2022 |
|
Alice Bradbury Professor Nicola Curtin Dr Yvette Drew
| The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response | 2022 |
|
Victoria Chamberlain Dr Yvette Drew Professor John Lunec
| Tipping growth inhibition into apoptosis by combining treatment with MDM2 and WIP1 inhibitors in p53WT uterine leiomyosarcoma | 2022 |
|